Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Sarasota Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$1,746,208

174 payments

Through program year 2025, Sarasota Clinical Research is reported as receiving $1,746,208 in research payments, across 174 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $304,550 21
2024 Research $300,680 35
2023 Research $305,407 25
2022 Research $208,553 16
2021 Research $219,216 29
2020 Research $288,595 24
2019 Research $119,206 24

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $504,309 19 payments
  2. AstraZeneca Pharmaceuticals LP $336,080 9 payments
  3. GlaxoSmithKline, LLC. $309,314 23 payments
  4. Teva Pharmaceuticals USA, Inc. $240,849 52 payments
  5. Chiesi USA, Inc. $187,327 29 payments
  6. Mylan Specialty L.P. $137,265 22 payments
  7. Sanofi US Services Inc. $28,629 4 payments
  8. ALK-Abello, Inc $1,713 2 payments
  9. Cipla USA Inc. $722 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para $309,314 23 payments
  2. A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) $304,951 6 payments
  3. A Multi Center Randomized Double Blind Active and Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihis $217,735 2 payments
  4. A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $179,274 28 payments
  5. A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $101,514 12 payments
  6. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $96,000 14 payments
  7. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $91,327 15 payments
  8. A Multi Center Randomized Double Blind Active and Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihistamines $80,348 1 payment
  9. A 24 Week Multicenter Double Blind Placebo Controlled Dose Ranging Study to Investigate the Efficacy and Safety of Oral Qbw251 in COPD Patients on Triple Therapy (Laba/Lama/Ics) $65,929 3 payments
  10. A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista $64,494 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record